Psychiatr. praxi. 2022;23(3):167-171 [Neurol. praxi. 2022;23(5):400-405]

Regular monitoring of cognitive functions in multiple sclerosis

Mgr. Jiří Motýl, Ph.D., doc. MUDr. Tomáš Uher, Ph.D.
Centrum pro demyelinizační onemocnění, Neurologická klinika a Centrum klinických neurověd, 1. lékařská fakulta, Univerzita Karlova a Všeobecná fakultní nemocnice v Praze

Prevalence of cognitive impairment in multiple sclerosis (MS) is reported to be in range between 35% and 65%. Cognitive impairment in MS has usually a mild form with information processing speed and episodic memory being the most affected cognitive domains. Annual neuropsychological screening of people with MS can provide clinicians with useful data on disease activity and progression; even before the threshold for cognitive impairment is reached. Neuropsychological test batteries BICAMS, MACFIMS or the SDMT test are recommended as the tools of choice for neuropsychological monitoring of MS. The change in cognitive outcomes can be evaluated by Reliable Change Index (RCI) or Standardized Regression Based (SRB) change norm.

Keywords: multiple sclerosis, neuropsychology, cognition, cognitive decline, SDMT, BICAMS, MACFIMS, reliable change index, cognitive screening.

Published: October 25, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Motýl J, Uher T. Regular monitoring of cognitive functions in multiple sclerosis. Psychiatr. praxi. 2022;23(3):167-171.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Amato MP. A decline in cognitive function should lead to a change in disease­‑modifying therapy - Commentary. Multiple Sclerosis Journal. 2018;24(13):1685-1686. doi:10.1177/1352458518787721. Go to original source... Go to PubMed...
    2. Amato MP, Krupp LB. Disease­‑modifying therapy aids cognition in multiple sclerosis. Nature Reviews Neurology. 2020;16(10):525-526. doi:10.1038/s41582-020-0383-x. Go to original source... Go to PubMed...
    3. Benedict RH, Amato MP, Boringa J, et al. Brief International Cognitive Assessment for MS (BICAMS): international standards for validation. BMC Neurol. 2012;12:55. doi:10.1186/1471-2377-12-55. Go to original source... Go to PubMed...
    4. Benedict RH, Morrow S, Rodgers J, et al. Characterizing cognitive function during relapse in multiple sclerosis. Mult Scler. 2014;20(13):1745-1752. doi:10.1177/1352458514533229. Go to original source... Go to PubMed...
    5. Benedict RHB, Amato MP, DeLuca J, Geurts JJG. Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. The Lancet Neurology. 2020;19(10):860-871. doi:10.1016/s1474-4422(20)30277-5 Go to original source... Go to PubMed...
    6. Benedict RHB, Cookfair D, Gavett R, et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). Journal of the International Neuropsychological Society. 2006;12(04). doi:10.1017/s1355617706060723. Go to original source... Go to PubMed...
    7. Benedict RHB, DeLuca J, Enzinger C, et al. Neuropsychology of Multiple Sclerosis: Looking Back and Moving Forward. J Int Neuropsychol Soc. 2017;23(9-10):832-842. doi:10.1017/S1355617717000959. Go to original source... Go to PubMed...
    8. Benedict RHB, Pol J, Yasin F, et al. Recovery of cognitive function after relapse in multiple sclerosis. Mult Scler. 2020;1352458519898108. doi:10.1177/1352458519898108. Go to original source... Go to PubMed...
    9. Brandstadter R, Fabian M, Leavitt VM, et al. Word­‑finding difficulty is a prevalent disease­‑related deficit in early multiple sclerosis. Multiple Sclerosis Journal. 2020;26(13):1752-1764. doi:10.1177/1352458519881760. Go to original source... Go to PubMed...
    10. Cígler H, Šmíra M. Chyba měření a odhad pravého skóru: Připomenutí některých postupů Klasické testové teorie. Testfórum. 2015;4(6). doi:10.5817/tf2015-6-104. Go to original source...
    11. Cortese M, Riise T, Bjornevik K, et al. Preclinical disease activity in multiple sclerosis: A prospective study of cognitive performance prior to first symptom. Ann Neurol. 2016;80(4):616-624. doi:10.1002/ana.24769. Go to original source... Go to PubMed...
    12. D'Hooghe MB, De Cock A, Van Remoortel A, et al. Correlations of health status indicators with perceived neuropsychological impairment and cognitive processing speed in multiple sclerosis. Multiple Sclerosis and Related Disorders. 2020;39:101904. doi:10.1016/j.msard.2019.101904. Go to original source... Go to PubMed...
    13. De Meo E, Portaccio E, Giorgio A, et al. Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis. JAMA Neurology. 2021;78(4):414. doi:10.1001/jamaneurol.2020.4920. Go to original source... Go to PubMed...
    14. Dobson R, Giovannoni G. Multiple sclerosis - a review. European Journal of Neurology. 2019;26(1):27-40. doi:10.1111/ene.13819. Go to original source... Go to PubMed...
    15. Dusankova JB, Kalincik T, Havrdova E, Benedict RH. Cross cultural validation of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) and the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Clin Neuropsychol. 2012;26(7):1186-1200. doi:10.1080/13854046.2012.725101. Go to original source... Go to PubMed...
    16. Fuchs TA, Ziccardi S, Dwyer MG, Response heterogeneity to home­‑based restorative cognitive rehabilitation in multiple sclerosis: An exploratory study. Mult Scler Relat Disord. 2019;34:103-111. doi:10.1016/j.msard.2019. 06. 026. Go to original source... Go to PubMed...
    17. Giedraitiene N, Kaubrys G, Kizlaitiene R Cognition During and After Multiple Sclerosis Relapse as Assessed With the Brief International Cognitive Assessment for Multiple Sclerosis. Sci Rep. 2018;8(1):8169. doi:10.1038/s41598-018-26449-7. Go to original source... Go to PubMed...
    18. Harel Y, Kalron A, Menascu S, et al. Cognitive function in multiple sclerosis: A long­‑term look on the bright side. PLoS One. 2019;14(8):e0221784. doi:10.1371/journal.pone.0221784. Go to original source... Go to PubMed...
    19. Heilbronner RL, Sweet JJ, Attix DK, et al. Official position of the american academy of clinical neuropsychology on serial neuropsychological assessments: the utility and challenges of repeat test administrations in clinical and forensic contexts. The Clinical Neuropsychologist. 2010;24(8):1267-1278. doi:10.1080/13854046.2010.526785. Go to original source... Go to PubMed...
    20. Hughes AJ, Bhattarai J, Jagriti PS, Beier M. Depressive symptoms and fatigue as predictors of objective­‑subjective discrepancies in cognitive function in multiple sclerosis. Multiple Sclerosis and Related Disorders. 2019;30:192-197. doi:10.1016/j.msard.2019. 01. 055. Go to original source... Go to PubMed...
    21. Chen MH, Chiaravalloti ND, Deluca J. Neurological update: cognitive rehabilitation in multiple sclerosis. Journal of Neurology. 2021;268(12):4908-4914. doi:10.1007/s00415-021-10618-2. Go to original source... Go to PubMed...
    22. Julian L, Merluzzi NM, Mohr DC. The relationship among depression, subjective cognitive impairment, and neuropsychological performance in multiple sclerosis. Mult Scler. 2007;13(1):81-86. doi:10.1177/1352458506070255. Go to original source... Go to PubMed...
    23. Kalb R, Beier M, Benedict RH, et al. Recommendations for cognitive screening and management in multiple sclerosis care. Mult Scler. 2018;24(13):1665-1680. doi:10.1177/1352458518803785. Go to original source... Go to PubMed...
    24. Kramer AF, Hahn S, Cohen NJ, et al. Ageing, fitness and neurocognitive function. Nature. 1999;400(6743):418-419. doi:10.1038/22682. Go to original source... Go to PubMed...
    25. Labiano­‑Fontcuberta A, Costa­‑Frossard L, Sainz de la Maza S, et al. The effect of timing of high­‑efficacy therapy on processing speed performance in multiple sclerosis. Multiple Sclerosis and Related Disorders. 2022;64. doi:10.1016/j.msard.2022.103959. Go to original source... Go to PubMed...
    26. Landmeyer NC, Burkner PC, Wiendl H, et al. Disease­‑modifying treatments and cognition in relapsing­‑remitting multiple sclerosis: A meta­‑analysis. Neurology. 2020;94(22):e2373-e2383. doi:10.1212/WNL.0000000000009522. Go to original source... Go to PubMed...
    27. Langdon DW, Amato MP, Boringa J, et al. Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Mult Scler. 2012;18(6):891-898. doi:10.1177/1352458511431076. Go to original source... Go to PubMed...
    28. Leavitt VM, Brandstadter R, Fabian M, et al. Dissociable cognitive patterns related to depression and anxiety in multiple sclerosis. Mult Scler. 2020;26(10):1247-1255. doi:10.1177/1352458519860319. Go to original source... Go to PubMed...
    29. Lebrun C, Blanc F, Brassat DJ, et al. Cognitive function in radiologically isolated syndrome. Mult Scler. 2010;16(8):919-925. doi:10.1177/1352458510375707. Go to original source... Go to PubMed...
    30. Martínez­‑González AE, Piqueras JA. Long­‑term effectiveness of combined cognitive­‑behavioral and neuropsychological intervention in a case of multiple sclerosis. Neurocase. 2015;21(5):584-591. doi:10.1080/13554794.2014.960425. Go to original source... Go to PubMed...
    31. Meli R, Roccatagliata L, Capello E, et al. Ecological impact of isolated cognitive relapses in MS. Mult Scler. 2020;26(1): 114-117. doi:10.1177/1352458518813722. Go to original source... Go to PubMed...
    32. Morrow SA, Drake A, Zivadinov R, et al. Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline. Clin Neuropsychol. 2010;24(7):1131-1145. doi:10.1080/13854046.2010.511272. Go to original source... Go to PubMed...
    33. Motyl J, Friedova L, Vaneckova M, et al. Isolated Cognitive Decline in Neurologically Stable Patients with Multiple Sclerosis. Diagnostics (Basel). 2021;11(3). doi:10.3390/diagnostics11030464. Go to original source... Go to PubMed...
    34. Pardini M, Uccelli A, Grafman J, et al. Isolated cognitive relapses in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014;85(9):1035-1037. doi:10.1136/jnnp-2013-307275. Go to original source... Go to PubMed...
    35. Portaccio E. A decline in cognitive function should lead to a change in disease­‑modifying therapy - No. Multiple Sclerosis Journal. 2018;24(13):1683-1684. doi:10.1177/1352458518783357. Go to original source... Go to PubMed...
    36. Rao SM. A manual for the Brief Repeatable Battery of Neuropsychological Tests in Multiple Sclerosis. New York: National Multiple Sclerosis Society. 1990.
    37. Rao SM. Role of Computerized Screening in Healthcare Teams: Why Computerized Testing is Not the Death of Neuropsychology. Archives of Clinical Neuropsychology. 2018;33(3):375-378. doi:10.1093/arclin/acx137 Go to original source... Go to PubMed...
    38. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology. 1991;41(5):685-691. doi:10.1212/wnl.41. 5. 685. Go to original source... Go to PubMed...
    39. Rao SM, Leo GJ, Haughton VM, et al. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology. 1989;39(2):161-161. doi:10.1212/wnl.39. 2. 161. Go to original source...
    40. Rao SM, Losinski G, Mourany L, et al. Processing speed test: Validation of a self­‑administered, iPad((R))-based tool for screening cognitive dysfunction in a clinic setting. Mult Scler. 2017;23(14):1929-1937. doi:10.1177/1352458516688955. Go to original source... Go to PubMed...
    41. Ruano L, Portaccio E, Goretti B, et al. Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. Mult Scler. 2017;23(9):1258-1267. doi:10.1177/1352458516674367. Go to original source... Go to PubMed...
    42. Ruet A. Do isolated cognitive relapses exist? Commentary. Multiple Sclerosis Journal. 2021;27(10):1489-1490. doi:10.1177/13524585211034123. Go to original source... Go to PubMed...
    43. Sandroff BM, Motl RW, Scudder MR, Deluca J. Systematic, Evidence­‑Based Review of Exercise, Physical Activity, and Physical Fitness Effects on Cognition in Persons with Multiple Sclerosis. Neuropsychology Review. 2016;26(3):271-294. doi:10.1007/s11065-016-9324-2. Go to original source... Go to PubMed...
    44. Scarpazza C, De Rossi N, Moiola L, et al. The still under­‑investigated role of cognitive deficits in PML diagnosis. Multiple Sclerosis and Demyelinating Disorders. 2017;2(1). doi:10.1186/s40893-016-0018-7. Go to original source...
    45. Schoonheim MM, Meijer KA, Geurts JJ. Network collapse and cognitive impairment in multiple sclerosis. Front Neurol. 2015;6:82. doi:10.3389/fneur.2015.00082. Go to original source... Go to PubMed...
    46. Smith A. Symbol Digit Modalities Test (SDMT): Manual. Los Angeles, CA: Western Psychological Services; 1982.
    47. Strober LB, Bruce JM, Arnett PA, et al. A much needed metric: Defining reliable and statistically meaningful change of the oral version Symbol Digit Modalities Test (SDMT). Multiple Sclerosis and Related Disorders. 2022;57:103405. doi:10.1016/j.msard.2021.103405. Go to original source... Go to PubMed...
    48. Sumowski JF, Benedict R, Enzinger C, et al. Cognition in multiple sclerosis: State of the field and priorities for the future. Neurology. 2018;90(6):278-288. doi:10.1212/WNL.0000000000004977. Go to original source... Go to PubMed...
    49. Sumowski JF, Leavitt VM. Cognitive reserve in multiple sclerosis. Mult Scler. 2013;19(9):1122-1127. doi:10.1177/1352458513498834. Go to original source... Go to PubMed...
    50. Sumowski JF, Rocca MA, Leavitt VM, et al. Brain reserve and cognitive reserve protect against cognitive decline over 4.5 years in MS. Neurology. 2014;82(20):1776-1783. doi:10.1212/WNL.0000000000000433. Go to original source... Go to PubMed...
    51. Uher T, Blahova­‑Dusankova J, Horakova D, et al. Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome. J Neurol. 2014;261(9):1735-1744. doi:10.1007/s00415-014-7413-9. Go to original source... Go to PubMed...
    52. Uher T, Krasensky J, Sobisek L, et al. Cognitive clinico­‑radiological paradox in early stages of multiple sclerosis. Ann Clin Transl Neurol. 2018;5(1):81-91. doi:10.1002/acn3.512. Go to original source... Go to PubMed...
    53. Uher T, Vaneckova M, Sormani MP, et al. Identification of multiple sclerosis patients at highest risk of cognitive impairment using an integrated brain magnetic resonance imaging assessment approach. Eur J Neurol. 2017;24(2):292-301. doi:10.1111/ene.13200. Go to original source... Go to PubMed...
    54. Weinstock­‑Guttman B, Eckert S, Benedict RH. A decline in cognitive function should lead to a change in disease­‑modifying therapy - Yes. Multiple Sclerosis Journal. 2018;24(13):1681-1682. doi:10.1177/1352458518783364. Go to original source... Go to PubMed...
    55. Weinstock Z, Morrow S, Conway D, et al. Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology. Mult Scler. 2021;13524585211049397. doi:10.1177/13524585211049397. Go to original source... Go to PubMed...
    56. Westervelt HJ. Dementia in Multiple Sclerosis: Why Is It Rarely Discussed? Archives of Clinical Neuropsychology. 2015;30(2):174-177. doi:10.1093/arclin/acu095. Go to original source... Go to PubMed...
    57. Wojcik CM, Beier M, Costello K, et al. Computerized neuropsychological assessment devices in multiple sclerosis: A systematic review. Multiple Sclerosis Journal. 2019;25(14): 1848-1869. doi:10.1177/1352458519879094. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.